Public Market Funding For Leading Cancer Fighting Companies

Mentor Capital targets to efficiently raise approximately $125 Million from warrant proceeds for operating cancer companies often like those in the Cancer Immunotherapy Index and to invest in those or related leading-edge firms via stock purchase or acquisition.

Mentor’s key advantage is to seek in depth medical science judgment to screen cancer breakthroughs for probable success well in advance of the FDA process. In the Mentor program, an identified cancer company enters into a Long-term Equity Funding Agreement with Mentor Capital. Mentor receives cancer related shares that are held in escrow until the associated investment payable is retired. The cancer fighting company receives cash from warrant proceeds at an agreed upon fixed price. The mutually related funding contracts speed up payment to the cancer companies growing most quickly.

Financially, Mentor Capital was specifically structured to facilitate future fundraising. MNTR began with few shares and stepped freely tradable warrants at $0.65, $1, $3, and with a large majority at $7 per share. The shares that spring from the warrants are immediately freely trading. The warrants are callable when the shares are $1 per share in the money. They must be exercised within 30 - 90 days as management best determines. Otherwise, warrants may be redeemed for 10 cents and passed to other designees to exercise. In this fashion, it is more highly likely than the normal case that significant warrant proceeds, now structured to equal at least $125 Million, will be eventually received by the Company.

A significant component of the Mentor Capital plan is to prepare for self-registration and to move off of the Pink Sheets. Similarly, Mentor has discussed with its original market maker the process to file a secondary 15(c)2-11 and make a market in the warrants. All of these procedural steps may allow for more robust trading in the stock.